Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATFurniture, Fixtures and OtherLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

CytomX Therapeutics (CTMX) Receivables - Net (2016 - 2025)

CytomX Therapeutics' Receivables - Net history spans 12 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Receivables - Net fell 35.13% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 35.13%, while the annual FY2025 figure was $2.0 million, 35.13% down from the prior year.
  • Receivables - Net reached $2.0 million in Q4 2025 per CTMX's latest filing, up from $1.6 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $36.0 million in Q4 2022 to a low of $756000.0 in Q1 2021.
  • Average Receivables - Net over 5 years is $4.1 million, with a median of $1.9 million recorded in 2023.
  • Peak YoY movement for Receivables - Net: tumbled 99.42% in 2021, then skyrocketed 4455.19% in 2022.
  • A 5-year view of Receivables - Net shows it stood at $790000.0 in 2021, then surged by 4455.19% to $36.0 million in 2022, then plummeted by 90.46% to $3.4 million in 2023, then fell by 9.59% to $3.1 million in 2024, then crashed by 35.13% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Receivables - Net are $2.0 million (Q4 2025), $1.6 million (Q3 2025), and $1.9 million (Q2 2025).